{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:43:36Z","timestamp":1761155016267,"version":"3.33.0"},"reference-count":8,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":6988,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[1987,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Forty\u2010five evaluable patients with stage IIIB carcinoma of the uterine cervix were entered into a prospective, double\u2010biind, randomized study to evaluate the possible radiation\u2010potentiating properties of hydroxyurea. All patients were documented to be without para\u2010aortic lymph node metastasis by pretherapy staging para\u2010aortic lymphadenectomy. The original plan of therapy was for continuous therapy (200 rads\/day) of 6,000 rads of pelvic radiation for 6 weeks plus intrauterine radium. However, 16 patients received 6,000 rads in 8 weeks by split\u2010course therapy (2\u2010week rest after 3,000 rads) plus radium. Twenty\u2010nine patients received the planned continuous therapy. The median dose of pelvic radiation for patients who received continuous therapy or split\u2010course radiation was 6,000 rads. Leukopenia (WBC &lt; 2,500\/mm<jats:sup>3<\/jats:sup>) was significantly increased in the patients given hydroxyurea as compared to those given placebo (P &lt; .001). There was no statistically significant difference relative to anemia, thrombocytopenia, radiation skin reaction, diarrhea, or radiation\u2010induced complications requiring surgical correction. The estimated 5\u2010year progression\u2010free survival rate for the combined, continuous, and split\u2010course radiation therapy hydroxyurea patients was 60 %, and its was 52 % for the corresponding placebo patients (P = .49). However, the estimated 5\u2010year progression free survival rate for the correctly treated patients (continuous therapy) was 91% for the hydroxyurea group and 60% for the placebo group (P &lt; .06).<\/jats:p>","DOI":"10.1002\/jso.2930350214","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T11:18:07Z","timestamp":1171970287000},"page":"129-134","source":"Crossref","is-referenced-by-count":35,"title":["Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer"],"prefix":"10.1002","volume":"35","author":[{"given":"M. Steven","family":"Piver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitune","family":"Vongtama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence J.","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(74)90347-0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(77)90580-4"},{"key":"e_1_2_1_4_2","first-page":"17","article-title":"The value of pretherapy para\u2010Aortic lymphadenectomy for carcinoma of the cervix uteri","volume":"45","author":"Piver MS","year":"1977","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(83)90043-1"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(85)90370-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life\u2010Tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"JR Stat Soc B"},{"key":"e_1_2_1_9_2","first-page":"124","article-title":"Radiotherapy with or without midonidazole in patients with stage IIIB or IVB squamous cell carcinoma of the uterine cervix","volume":"4","author":"Leibel S","year":"1985","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.2930350214","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.2930350214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:33:09Z","timestamp":1736807589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.2930350214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,6]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1987,6]]}},"alternative-id":["10.1002\/jso.2930350214"],"URL":"https:\/\/doi.org\/10.1002\/jso.2930350214","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"type":"print","value":"0022-4790"},{"type":"electronic","value":"1096-9098"}],"subject":[],"published":{"date-parts":[[1987,6]]}}}